Inflammasome therapeutics to enter clinic with treatment for dry amd

Newton, mass.--(business wire)-- #nrtis--inflammasome therapeutics (https://inflam.com), a private company, developing a new class of inflammasome inhibitor drugs called kamuvudines as therapies for prevalent, degenerative diseases, announced the fda has granted approval for the opening of a phase 1/2 clinical trial of the company's drug for the treatment of geographic atrophy (ga), the most severe form of dry amd. this is the first clinical trial of an inflammasome inhibitor to treat ga. paul ashton, c.
AMD Ratings Summary
AMD Quant Ranking